What's New in GI Pharmacology Course
Friday, October 5, 2018

Course Directors: Brooks D. Cash, MD, FACG, and William D. Chey, MD, FACG

ACG's What's New in GI Pharmacology Course provides an intensive review of GI pharmacology, including comparisons and contrasts between conventional and emerging pharmacological treatment options for a variety of GI disorders. Topics presented at this course included use of biosimilars to treat IBD, treatment options for functional GI disorders, review of new anticoagulants, a GI's guide to vaccinations, pharmacological therapy during pregnancy, treatment options for primary biliary cirrhosis, and medico-legal issues in pharmacology. The course is designed primarily for physicians in GI/hepatology, as well as physician assistants, nurse practitioners, and other advanced practice healthcare professionals interested in the latest information on state-of-the-art treatment of these illnesses.

Functional Dyspepsia: Current Pharmacologic Approaches
William D. Chey, MD, FACG
Identify the epidemiology, diagnostic processes, and best practices for the management of functional dyspepsia.

Contemporary Review of PPI Therapy: What You and Your Patients Need to Know
Stuart J. Spechler, MD, FACG
Discuss the clinical evidence for the use of PPIs in a variety of clinical scenarios, and review current evidence regarding short- and long-term safety of PPIs.

Approach to Symptomatic Diverticular Disease
Lisa L. Strate, MD, MPH, FACG
Describe the various presentations of symptomatic diverticular disease, and review current therapeutic approaches.

Antibiotic Prophylaxis for the Gastroenterologist
Michelle A. Anderson, MD, MSc
Explain the evidence for and against the application of antibiotic prophylaxis in patients with gastroenterological diseases or undergoing endoscopic procedures.

Pharmacologic Approach to Chronic Constipation and IBS-C
Brooks D. Cash, MD, FACG
Define current and emerging pharmacologic treatment options for constipation, including chronic idiopathic constipation, opioid-induced constipation, and IBS-C.

Medical Management of Fatty Liver Disease
Phillip K. Henderson, DO
Discuss the issues and interventions currently available for the management of patients with fatty liver disease, with a focus on available pharmacologic approaches.

Chemoprevention for Gastrointestinal Malignancies
John M. Inadomi, MD, FACG
Identify the evidence for and against chemoprevention for malignancies of the gastrointestinal tract and provide recommendations for appropriate use.

Personalized IBD Management: Best Practices for Therapeutic Drug Monitoring and for Managing Treatment Failures
David T. Rubin, MD, FACG
Outline therapeutic drug monitoring in IBD patients, and how to optimize immunosuppressive drug therapy with regard to adjusting therapy in class or switching classes of biologics.